Aelis Farma Announces its 2023 Financial Calendar
BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible) (Paris: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces its indicative financial calendar for the financial year 2023. Event Date of release* 2022 Annual Results Monday, April 3, 2023 Annual General Meeting Wednesday, May 24, 2023 2023 Half-Year Results Monday, September 25, 2023 (*) The press releases will be issued after the close of trading. Information may be subject to change. About AELIS FARMA Founded in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi). These new molecular entities hold great potential in the treatment of many brain diseases. CB1-SSi were developed by Aelis Farma on the basis of the discovery of a new natural defense mechanism of ...